In vivo interferon-alpha/ribavirin treatment modulates Vγ9Vδ2 T-cell function during chronic HCV infection
| Autor: | Hélène Sicard, Chiara Agrati, Gianpiero D'Offizi, Maria Rosaria Capobianchi, Chrysoula Vlassi, Federico Martini, Cécile Bonnafous, Eleonora Cimini |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Time Factors medicine.medical_treatment T cell Immunology Alpha interferon Hepacivirus Antiviral Agents Virus chemistry.chemical_compound Interferon-gamma Immune system In vivo Interferon Virology Ribavirin Medicine Humans Clonal Anergy business.industry Interferon-alpha Receptors Antigen T-Cell gamma-delta Cell Biology Immunotherapy Hepatitis C Chronic Middle Aged medicine.anatomical_structure chemistry Female business medicine.drug |
| Zdroj: | Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 33(3) |
| ISSN: | 1557-7465 |
| Popis: | In chronic hepatitis C virus (HCV) infection, treatment failure and defective host immune response highly demand improved therapy strategies. Vγ9Vδ2 T-cells represent a good target for HCV immunotherapy, since phosphoantigen (PhAg)-activated Vγ9Vδ2 T-lymphocytes are able to inhibit subgenomic HCV replication by interferon (IFN)-γ release. A profound impairment of IFN-γ production by Vγ9Vδ2 T-cells during chronic HCV infection was previously shown. Interestingly, in vitro IFN-α partially restored Vγ9Vδ2 T-cells responsiveness to PhAg, by stabilizing IFN-γ-mRNA. To verify how in vivo IFN-α/ribavirin (RBV) treatment could affect Vγ9Vδ2 T-cells phenotype and responsiveness to PhAg in HCV-infected patients, 10 subjects underwent a longitudinal study before and after treatment. IFN-α/RBV therapy did not significantly modify Vγ9Vδ2 T-cell numbers and differentiation profile. Interestingly, Vγ9Vδ2 T-cell responsiveness remained unmodified until 3 weeks of therapy, but dropped after 1 month, suggesting that repeated in vivo IFN-α administration in the absence of T-cell receptor (TCR)-mediated signals results in Vγ9Vδ2 T-cell anergy. The present work defines the window of possible application of combined strategies targeting Vγ9Vδ2 T-cells during chronic HCV infection; specifically, the first 3 weeks from the beginning of treatment may represent the optimal time to target Vγ9Vδ2 T-cells in vivo, since their function in terms of IFN-γ production is preserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|